Study of Predictive Factors of Chemoresistance in Ovarian Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02878122

Acronym

FaCliBioCCo

Enrollment

Registered

2016-08-25

Start date

2015-03-31

Completion date

2020-03-31

Last updated

2021-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Keywords

ovarian cancer, chemo resistance, predictive factors, cohort study, bio bank

Brief summary

Epithelial ovarian cancer (EOC) has a poor prognosis. EOC management requires debulking surgery and chemotherapy based on taxol and carboplatine. Initial response is often good, but most often a recurrence occurred in the first 18 months. Early recurrence signs chemoresistance and palliative treatment. The study of predictive clinical or biological factors is required to adapt therapeutic and develop new treatments.

Interventions

PROCEDURECancer treatment

Chemotherapy and laparoscopic surgery

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patient \> 18 years of age * patient with histological proven epithelial ovarian cancer

Exclusion criteria

* patients who can not give their own consent * patients without ovarian cancer

Design outcomes

Primary

Measure	Time frame
Chemoresistance defined by clinical recurrence	6 months after the end of chemotherapy
Chemoresistance defined by biological recurrence	6 months after the end of chemotherapy
Chemoresistance defined by radiological recurrence	6 months after the end of chemotherapy

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026